Allen-Bradley 20G11GB2P2JA0NNNNN

The part number 20G11GB2P2JA0NNNNN is associated with an advanced clinical research study examining the effectiveness and safety of danuglipron, an oral glucagon-like peptide-1 receptor agonist, in the treatment of type 2 diabetes and obesity. This randomized, placebo-controlled Phase 2 trial aims to compare the impact of danuglipron with insulin therapy on blood glucose management and weight reduction among patients aged 18-99 with a body mass index of 25 or higher. Over a 12-week period, the study will monitor changes in metabolic parameters, ensuring a structured assessment of danuglipron's tolerability and pharmacodynamics. With 18 participants involved, the trial is meticulously designed to provide insights into both efficacy and safety for individuals at risk of heart disease or stroke, all while adhering to rigorous clinical research protocols.